# Vanda Pharmaceuticals (VNDA) — Earnings

VNDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vnda/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$1.04 |
| EPS estimate | −$0.58 |
| EPS surprise | −78.54% |
| Revenue surprise | −18.40% |
| Revenue | $50.5M |
| Revenue estimate | $61.9M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/3e243196-7819-c42c-5e46-61157098fa26.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.58 | −$1.04 | -78.54% | $61.9M | $50.5M |
| Q1 2026 | May 6, 2026 | −$0.69 | −$0.82 | -19.19% | $55.0M | $51.7M |
| Q4 2025 | Feb 11, 2026 | −$0.98 | −$2.39 | -145.13% | $59.3M | $57.2M |
| Q3 2025 | Oct 29, 2025 | −$0.43 | −$0.38 | 12.30% | $58.8M | $56.3M |
| Q2 2025 | Jul 31, 2025 | −$0.36 | −$0.46 | -28.96% | $54.8M | $52.6M |
| Q1 2025 | May 7, 2025 | −$0.57 | −$0.50 | 12.79% | $45.1M | $50.0M |
| Q4 2024 | Feb 13, 2025 | −$0.11 | −$0.08 | 25.02% | $52.2M | $53.2M |
| Q3 2024 | Nov 6, 2024 | −$0.16 | −$0.09 | 42.57% | $49.2M | $47.7M |
| Q2 2024 | Jul 31, 2024 | −$0.19 | −$0.08 | 57.89% | $47.9M | $50.5M |
| Q1 2024 | May 8, 2024 | $0.05 | −$0.07 | -240.00% | $48.5M | $47.5M |
| Q4 2023 | Feb 7, 2024 | −$0.09 | −$0.04 | 55.56% | $37.0M | $45.3M |
| Q3 2023 | Nov 8, 2023 | −$0.04 | $0.00 | 100.00% | $44.5M | $38.8M |
| Q2 2023 | Jul 27, 2023 | −$0.13 | $0.03 | 123.08% | $49.0M | $46.1M |
| Q1 2023 | May 3, 2023 | $0.00 | $0.06 | 0.00% | — | $62.5M |
| Q4 2022 | Feb 8, 2023 | $0.08 | $0.12 | 50.00% | $67.6M | $64.5M |
| Q3 2022 | Nov 2, 2022 | $0.10 | $0.06 | -40.00% | $71.0M | $65.3M |
| Q2 2022 | Aug 3, 2022 | $0.14 | $0.05 | -64.29% | $67.0M | $64.4M |
| Q1 2022 | May 5, 2022 | −$0.01 | −$0.11 | -1000.00% | $58.0M | $60.2M |
| Q4 2021 | Feb 23, 2022 | $0.09 | $0.12 | 41.18% | $70.0M | $68.0M |
| Q3 2021 | Nov 3, 2021 | $0.19 | $0.14 | -26.32% | $74.3M | $70.1M |

## Frequently Asked Questions

### When did Vanda Pharmaceuticals (VNDA) last report earnings?

Vanda Pharmaceuticals last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did VNDA beat earnings estimates?

No. Vanda Pharmaceuticals reported EPS of −$1.04 for Q2 2026 against a −$0.58 estimate — a 78.54% miss.

### How much revenue did VNDA report last quarter?

Vanda Pharmaceuticals reported $50.5M in revenue for Q2 2026, against a consensus estimate of $61.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).